Enzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of brain...
- Mechanism
- Curator reviewed
Enzastaurin is an oral serine-threonine kinase inhibitor that is designed to suppress tumor growth through multiple mechanisms. Preclinical data indicate it may reduce the cell's ability to reproduce (cell proliferation), increase the natural death of the tumor cells (apoptosis), and inhibit tumor- induced blood supply (angiogenesis). Enzastaurin has been shown to inhibit signaling through the PKC-B and PI3K/AKT pathways. These pathways have been shown to be activated in a wide variety of cancers. In addition to glioblastoma, enzastaurin is also being studied in multiple other tumor types, including non-Hodgkin's lymphoma, colorectal cancer, non-small cell lung cancer, pancreatic cancer, and mantle cell lymphoma.
- Primary indication
- Investigated for use/treatment in brain cancer, lymphoma (non-hodgkin's), and lung cancer.Curator reviewed
- Formula / weight
- C32H29N5O2 · 515.617 g/mol (avg)
- Code names
- LY-317615
Resolves to
AXRCEOKUDYDWLF-UHFFFAOYSA-NSMILESCN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CN(C2CCN(CC3=CC=CC=N3)CC2)C2=CC=CC=C12What you can answer from here — as of September 12, 2026
Which drugs share a target with Enzastaurin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account